Fig. 4

MET-CAR-T killing activity on MET highly amplified human cancer cells resistant to MET targeting agents. Analysis of cell viability after 3 days of treatments with different concentrations of anti-MET agents on human gastric carcinoma cells GTL-16_Res cells (A) or Cancer of Unknown Primary L1.13 cells (B). PHA-665752, Capmatinib, JNJ-605: small molecule Tyrosine Kinase Inhibitors targeting MET. MvDN30: a MET inhibitory antibody. Graphs report values as percentage of the untreated controls. (C) MET-CAR specific killing activity at different Effector:Target ratio versus GTL-16_Res (Top panels) and L1.13 (Bottom panel). NTD: Not-transduced T cells, #948/#949: MET-CAR-T. Bars: Standard Deviations. Statistical significance between NTD and MET-CAR-T was calculated by Two-way Anova, corrected Bonferroni. Stars indicated P values: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001